Status:

WITHDRAWN

Study of CAD-1883 for Spinocerebellar Ataxia

Lead Sponsor:

Cadent Therapeutics

Conditions:

Spinocerebellar Ataxias

Spinocerebellar Ataxia Type 1

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of Spinocerebellar Ataxia (SCA). T...

Detailed Description

This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of SCA using multiple dose levels....

Eligibility Criteria

Inclusion

  • Key
  • Prior Spinocerebellar Ataxia (SCA) diagnosis of the following SCA genotypes: SCA1, 2, 3, 6, 7, 8, 10, 17, or Autosomal Recessive Cerebellar Ataxia Type 1 (ARCA1).
  • Scale for the Assessment and Rating of Ataxia (SARA) Total score ≥8 and \<30 at Screening
  • SARA item #1 (gait) score of ≥2 at Screening
  • Ability to ambulate 8 meters at Screening without assistance from another person
  • Key

Exclusion

  • Neurological condition other than SCA that could predominantly explain or contribute significantly to the subjects' symptoms of ataxia or that could confound the assessment of ataxia symptoms (e.g., chronic alcoholism, vitamin deficiencies, multiple sclerosis, Parkinson's disease, Friedreich's ataxia, vascular disease, tumors, paraneoplastic disease, head injury, idiopathic late onset ataxia, multisystem atrophy, stroke, arthritis, cerebral palsy, spasticity of unknown origin).
  • Moderate or severe scores on the following Inventory of Non-Ataxia Signs (INAS) items at Screening: Dystonia: at least 3 of 5 items; Spasticity: at least 2 of 3 items; Rigidity: at least 2 of 3 items

Key Trial Info

Start Date :

June 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2022

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04301284

Start Date

June 1 2021

End Date

December 1 2022

Last Update

April 8 2021

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Collaborative Neuroscience Network

Long Beach, California, United States, 90806

2

UCLA Medical Center

Los Angeles, California, United States, 90095

3

University of Colorado

Aurora, Colorado, United States, 80045

4

University of Florida

Gainesville, Florida, United States, 32608